Personalis Inc Stock
Personalis Inc Stock
Personalis Inc shows a slight decrease today, losing -€0.002 (-0.170%) compared to yesterday.
Our community is currently high on Personalis Inc with 5 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is potential for a 153.81% increase which would mean more than doubling the current price of 1.18 € for Personalis Inc.
Our community identified positive and negative aspects for Personalis Inc stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Personalis Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Personalis Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Personalis Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Personalis Inc | -0.170% | -3.115% | -7.512% | -43.009% | -43.173% | -94.306% | - |
| Stoke Therapeutics Inc | -1.720% | -3.636% | -15.200% | - | - | - | - |
| Immuron | -0.900% | 1.852% | -5.983% | 26.437% | 31.737% | -50.000% | - |
Comments
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at Needham & Company LLC from $2.30 to $3.50. They now have a "buy" rating on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.30 price target on the stock.
Show more
Ratings data for PSNL provided by MarketBeat
News
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive